GENE ONLINE|News &
A Novel Tool to Augment Checkpoint Inhibitor Cancer Therapy
Washington University School of Medicine researchers uncover the mechanism by which tumor-infiltrating myeloid cells create suppressive microenvironments. The findings provide a novel approach for augmenting the effects of checkpoint blockade therapies.
The suppressive tumor environment affects T cell responses by engaging immune checkpoint proteins such as PD-1.
GO Prime with only $1.49 now
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
